Core Viewpoint - The clinical trial for HSK39297 tablets, aimed at treating primary IgA nephropathy, has been initiated, focusing on its efficacy and safety over a 48-week period [1][2]. Group 1: Clinical Trial Details - The trial is a multicenter, randomized, double-blind, placebo-controlled Phase III study with a registration number CTR20260278, first published on January 29, 2026 [1]. - The primary objective is to evaluate the effectiveness of HSK39297 in reducing proteinuria after 36 weeks and delaying the decline in renal function after 48 weeks in patients with primary IgA nephropathy [1]. - Secondary objectives include assessing the drug's effectiveness in delaying renal function decline and reducing proteinuria, as well as its impact on patients' quality of life and disease progression [1]. Group 2: Trial Endpoints - Primary endpoints include the ratio of 24-hour urine protein creatinine ratio (24h-UPCR) compared to baseline after 36 weeks and the annualized total slope of estimated glomerular filtration rate (eGFR) after 48 weeks [2]. - Secondary endpoints consist of various measures of eGFR and proteinuria at multiple time points (36, 48, and 104 weeks), as well as changes in plasma concentration of HSK39297 and adverse events during the study [2]. Group 3: Trial Status - The trial is currently ongoing and has not yet recruited participants, with a target enrollment of 370 individuals [3].

Policy Developments - The National Medical Products Administration (NMPA) aims for a drug inspection pass rate of over 99% by 2025, with 19,700 batches to be inspected, ensuring overall drug safety stability in the country [1] Drug and Device Approvals - Qianjin Pharmaceutical announced that it and its subsidiary received drug registration certificates for Dydrogesterone tablets, Baricitinib tablets (4mg, 2mg), and Dapagliflozin tablets (5mg, 10mg), enhancing its product pipeline for sustainable development [2] - Haizhi Pharmaceutical's subsidiary received acceptance for the listing application of HSK39297 tablets, intended for treating adults with paroxysmal nocturnal hemoglobinuria (PNH) who have not previously received complement inhibitors [3] - Xuantai Pharmaceutical obtained a drug registration certificate for injectable Isavuconazole, which is used to treat invasive aspergillosis and mucormycosis in adults [4] Capital Market Insights - Xiangyu Medical reported that as of the end of 2025, its brain-computer interface products have not achieved large-scale sales, with revenue contribution remaining minimal due to delays in bidding and sales processes [5] - Sanbo Brain Science clarified that it does not engage in the research, production, or sales of brain-computer interface products, and the revenue from neuro-regulation technology is negligible [6] - Weisi Medical stated that its new products in the brain-computer interface field are still in the early market cultivation stage, with limited revenue contribution [7] - Qiangna Technology, a "unicorn" in the brain-computer interface sector, completed approximately 2 billion RMB in financing, marking the second-largest financing in the field after Neuralink [8] - Baihua Pharmaceutical announced the termination of its control change plan due to a lack of consensus with the controlling shareholder, with stock resuming trading on January 7, 2026 [9] Industry Developments - Puluo Pharmaceutical signed a strategic cooperation framework agreement with Xi'an Xintong Pharmaceutical Research Co., Ltd. to collaborate on innovative drug research and outsourced production projects [10] - Yong'an Pharmaceutical plans to absorb and merge its wholly-owned subsidiary Hubei Ling'an Technology Co., Ltd., with recent financial data showing total assets of 180 million RMB and a net profit of -1.12 million RMB for the subsidiary [11] - Baiyang Pharmaceutical established a collaborative innovation laboratory with Capital Medical University Xuanwu Hospital to focus on cutting-edge medical research in neuroscience and thoracic surgery [12] - Insilico Medicine announced an $888 million collaboration with Servier for the development of anti-tumor drugs, with potential upfront payments and milestone payments involved [13] Public Sentiment Alerts - WuXi AppTec disclosed that shareholders controlled by the actual controller have cumulatively reduced their holdings by 59.6751 million shares, accounting for 2% of the total share capital, with the reduction completed on January 5, 2026 [14]

Core Viewpoint - The company has received a notice of acceptance from the National Medical Products Administration for its drug HSK39297, a selective complement factor B inhibitor aimed at treating paroxysmal nocturnal hemoglobinuria (PNH) in adult patients who have not previously received complement inhibitors [1][2][3] Group 1: R&D Project Overview - HSK39297 is a self-developed small molecule inhibitor that blocks the activation of the alternative pathway of the complement system, targeting diseases mediated by abnormal complement activation [2] - Clinical research indicates that HSK39297 has good safety and tolerability, showing significant therapeutic advantages over eculizumab in improving anemia, reducing transfusion needs, and alleviating fatigue symptoms [2] - The drug is classified as a Class 1 chemical drug in China and is the first-tier CFB inhibitor for PNH, addressing a significant unmet clinical need with promising market prospects [2] Group 2: Regulatory Approval and Clinical Trials - The application for HSK39297 has been prioritized for review due to its classification as an innovative drug for treating urgent clinical needs and rare diseases [3] - HSK39297 is currently undergoing Phase II clinical trials for lupus nephritis and is set to initiate Phase III clinical research for primary IgA nephropathy [3]

Market Strategy - The market continues to rise with increased volume, and the Shanghai Composite Index has broken through previous highs [5][10] - The overall A-share market saw a rise of 1.59%, with the Shanghai Composite Index up by 1.50% and the ChiNext Index up by 0.75% [7] - The performance of the hard technology sector is leading, while the innovation growth sector is lagging [8] Industry Dynamics - Global sodium-ion battery shipments are expected to reach 9 GWh in 2025, a year-on-year increase of 150% [26] - The main applications for sodium-ion batteries include energy storage, light electric vehicles, and AI data centers, with significant market share growth [27] - NVIDIA has launched the Rubin platform, designed for AI supercomputing, featuring six new chips that enhance training speed and reduce costs [28][29] Company Updates - Haizhi Science (002653.SZ) has received acceptance for its innovative drug HSK39297 for treating paroxysmal nocturnal hemoglobinuria [32] - Meiya Optoelectronics (002690) won a lawsuit with compensation exceeding 198 million yuan [34] - Yisheng (002458.SZ) reported a 40% year-on-year increase in white feather chick sales in December 2025, while breeding pig sales declined by 43% [36] - Shennong Group (605296.SH) sold 3.0742 million pigs in 2025, generating revenue of 4.729 billion yuan [38] - Taotao Vehicle (301345.SZ) expects a net profit of 800-850 million yuan for 2025, a year-on-year increase of 85.5%-97.1% [41] - Ugreen Technology (301606.SZ) anticipates a net profit of 653-733 million yuan for 2025, reflecting a growth of 41.26%-58.56% [43]

Core Viewpoint - The company, Haikang (002653), announced that its subsidiary Sichuan Haikang Pharmaceutical Co., Ltd. received a notice from the National Medical Products Administration regarding the acceptance of the registration application for the drug HSK39297, aimed at treating adult patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) who have not previously received complement inhibitors [1] Group 1 - The drug HSK39297 is classified as a Class 1 chemical drug according to China's new chemical drug registration classification regulations [1] - HSK39297 is the first-tier CFB inhibitor targeting PNH in China, addressing a significant unmet clinical need [1] - The market outlook for HSK39297 is positive due to the high demand for treatment options in this therapeutic area [1]

Core Viewpoint - The company announced that its subsidiary, Sichuan Hisun Pharmaceutical Co., Ltd., received a Notice of Acceptance from the National Medical Products Administration for its drug HSK39297, a selective complement factor B inhibitor aimed at treating diseases mediated by abnormal complement activation [1] Group 1 - HSK39297 is a self-developed small molecule inhibitor that effectively inhibits the activity of complement factor B, blocking the activation of the alternative pathway and the complement amplification cycle [1] - The drug is designed to control both C3b-mediated extravascular hemolysis and terminal complement-mediated intravascular hemolysis in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) [1] - HSK39297 acts at the proximal end of the complement cascade's alternative pathway, targeting the mechanisms that lead to hemolysis [1]

Core Viewpoint - Company Sichuan Haisco Pharmaceutical Co., Ltd. received a Notice of Acceptance from the National Medical Products Administration for HSK39297 tablets, which are intended for the treatment of adult patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) who have not previously received complement inhibitor therapy [1] Group 1 - The acceptance notice was issued on January 6, 2026 [1] - HSK39297 is specifically designed for adult patients with a history of not being treated with complement inhibitors [1]

Core Viewpoint - Company Sichuan Hisun Pharmaceutical Co., Ltd., a subsidiary of Hisun Pharmaceutical (002653.SZ), received a Notice of Acceptance from the National Medical Products Administration for the drug HSK39297 tablets, aimed at treating adult patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) who have not previously received complement inhibitor therapy [1] Group 1 - The drug HSK39297 is specifically indicated for adult patients with PNH [1] - The acceptance notice was issued on January 6, 2026 [1] - The drug is intended for patients who have not undergone prior treatment with complement inhibitors [1]

Group 1 - The core point of the article is that the company, Hisun Pharmaceutical (002653), announced that its subsidiary, Sichuan Hisun Pharmaceutical Co., Ltd., received a "Notice of Acceptance" from the National Medical Products Administration for a new drug application [1] - The drug in question is named HSK39297 tablets, which is intended for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who have not previously received complement inhibitor therapy [1]

Core Viewpoint - The announcement indicates that the company has received a marketing authorization for its innovative drug HSK39297, which targets a significant unmet clinical need in the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who have not previously received complement inhibitors [1] Group 1: Company Information - The company, Haikang Pharmaceutical, has a subsidiary named Sichuan Haikang Pharmaceutical Co., Ltd., which is responsible for the development of HSK39297 [1] - HSK39297 is positioned as a first-tier CFB inhibitor specifically for the treatment of PNH, highlighting its competitive edge in the market [1] Group 2: Market Potential - There is a substantial unmet clinical demand for treatments targeting PNH, suggesting a favorable market outlook for HSK39297 [1] - The drug's approval is expected to enhance the company's market presence in the therapeutic area of PNH, which is currently underserved [1]